Yudong He

Yudong is VP of Computational Biology at Inflammatix, focusing on research for novel multi-gene molecular diagnostic signatures. Prior to Inflammatix, he led Computational Biology/Bioinformatics teams at Amgen and Merck as Scientific Director to advance multiple programs for drug R & D pipeline in areas of target discovery & liability assessment, lead optimization, safety issue resolution & enablement of IND fillings. He was also responsible for developing new platforms and data integration strategies for biomarker identification, mechanism of action elucidation, predictive & translational safety modeling. Prior, at Rosetta Inpharmatics, he pioneered novel algorithms and genomic applications including the 70-gene breast cancer prognosis classifier as basis for the FDA-approved MammaPrint test. He has authored or co-authored more than 100 peer-reviewed publications and is inventor of more than 10 US patents. He received his PhD in Physics from the University of California, Berkeley and MBA from the University of Washington Forster School of Business.